Founder & CEO, Synklino Aps
Synklino strives to provide rapid relief as well as to improve long-term survival for transplant recipients by providing fast and safe eradication of cytomegalovirus (CMV) infections. For transplant recipients, CMV disease causes suboptimal transplantation outcome, increased morbidity, prolonged hospitalization and increased mortality. Our drug candidate SYNx efficiently eliminates both lytic as well as latently infected cells, and thereby potently inhibits viral replication and eradicates the virus - simply taking CMV out of the equation for the transplant recipient. SYNx highly potently, efficiently and selectively eliminates CMV infected cells through a proven mechanism, allowing for both stand-alone and combination therapy.